Advances in multiple myeloma therapy during two past decades

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10291741" target="_blank" >RIV/00216208:11110/14:10291741 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/14:10291741

Result on the web

<a href="http://dx.doi.org/10.1016/j.csbj.2014.05.005" target="_blank" >http://dx.doi.org/10.1016/j.csbj.2014.05.005</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.csbj.2014.05.005" target="_blank" >10.1016/j.csbj.2014.05.005</a>

Result language

angličtina

Original language name

Advances in multiple myeloma therapy during two past decades

Original language description

Multiple myeloma (MM) is a clonal B-cell malignancy characterized by aberrant expansion of plasma cells within bone marrow and extramedullary sites. It is one of the most common haematological malignancies; it accounts for 1.4% of all tumours and is responsible for 2% of cancer-related mortality. Over the last decades, the paradigm of MM therapy has changed dramatically - from the conventional combination of oral melphatan + prednisone, high-dose chemotherapy with stem cell (ASCT) support for younger patients to the present paradigm with the use of one (or more) of 3 major new targeted agents - the first-in class proteasome inhibitor bortezomib, the immunomodulatory drug thalidomide, and its more potent derivative lenalidomide. Their use as a part of initial therapy is associated with high overall response rates as well as high rates of complete response (CR), both for elderly patients unable to undergo ASCT and for younger patients treated prior to ASCT. Altogether, the advent of nove

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NT12215" target="_blank" >NT12215: Rationalization of therapy of multiple myeloma</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Computational and Structural Biotechnology Journal

ISSN

2001-0370

e-ISSN

—

Volume of the periodical

10

Issue of the periodical within the volume

16

Country of publishing house

SE - SWEDEN

Number of pages

3

Pages from-to

38-40

UT code for WoS article

—

EID of the result in the Scopus database

—